Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 38

Sort by

Sort Order Select

Journal Articles

Treatment of Immune Thrombocytopenia (ITP) with Eltrombopag (EPAG) in Patients Who Did and Did Not Receive Prior Rituximab (Ritux): A Post-Hoc Analysis of the Extend Study

Oliver Meyer, James B. Bussel, MD, Raymond S Wong, MBChB, MD, Abderrahim Khelif, Miona Stankovic, Joan Maier, Mansoor N. Saleh

Blood (2018) 132 (Supplement 1): 1152.

https://doi.org/10.1182/blood-2018-99-114694

Published: 2018

Journal Articles

Safety and efficacy of long-term treatment of chronic/persistent ITP with eltrombopag: final results of the EXTEND study

Raymond S. M. Wong, Mansoor N. Saleh, Abderrahim Khelif, Abdulgabar Salama, Maria Socorro O. Portella, Paul Burgess, James B. Bussel

Blood (2017) 130 (23): 2527–2536.

https://doi.org/10.1182/blood-2017-04-748707

Published: 2017

Includes: Supplemental data

Journal Articles

Occurrence and Management of Cataracts in Adult Patients (pts) with Chronic Immune Thrombocytopenia (cITP) during Long-Term Treatment with Eltrombopag (EPAG): Results from the Extend Study

Raymond SM Wong, MRCP,FRCP, Abderrahim Khelif, Abdulgabar Salama, Mansoor N. Saleh, Ozlem Ocak Arikan, Erhard Quebe-Fehling, PhD, James B. Bussel, MD

Blood (2017) 130 (Supplement 1): 1053.

https://doi.org/10.1182/blood.V130.Suppl_1.1053.1053

Published: 2017

Journal Articles

Hepatobiliary and Thromboembolic Events during Long-Term E.X.T.E.N.Ded Treatment with Eltrombopag in Adult Patients with Chronic Immune Thrombocytopenia (ITP)

Mansoor N. Saleh, James B Bussel, MD, Raymond SM Wong, Balkis Meddeb, Abdulgabar Salama, Ali El-Ali, Erhard Quebe-Fehling, PhD, Abderrahim Khelif

Blood (2016) 128 (22): 1368.

https://doi.org/10.1182/blood.V128.22.1368.1368

Published: 2016

Journal Articles

Efficacy of Eltrombopag in Adult East Asian and Non-East Asian Patients with Chronic Immune Thrombocytopenia (cITP): Results from the Extend Study

Raymond SM Wong, James B Bussel, MD, Mansoor N. Saleh, Abderrahim Khelif, Balkis Meddeb, Ali El-Ali, Erhard Quebe-Fehling, PhD, Abdulgabar Salama

Blood (2016) 128 (22): 4930.

https://doi.org/10.1182/blood.V128.22.4930.4930

Published: 2016

Journal Articles

Improvements in Patient Health-Related Quality of Life (HRQoL) with Clinical Efficacy in Patients Treated with Eltrombopag: Final Results from the Long-Term, Open-Label Extend Study

Mansoor N. Saleh, James B. Bussel, MD, Abderrahim Khelif, Paul Burgess, Ali El-Ali, Anuja Roy, Victoria Barghout, Mei Sheng Duh, Kelly M. Grotzinger, Abdulgabar Salama

Blood (2016) 128 (22): 3742.

https://doi.org/10.1182/blood.V128.22.3742.3742

Published: 2016

Journal Articles

Patient-Reported Health-Related Quality of Life Improves over Time in Patients with Chronic Immune Thrombocytopenia Receiving Long-Term Treatment with Eltrombopag

Abderrahim Khelif, Mansoor N. Saleh, Abdulgabar Salama, Paul Burgess, Maria do Socorro O Portella, Anuja Roy, Victoria Barghout, Jasmina I. Ivanova, Kelly M. Grotzinger, James B. Bussel, MD

Blood (2016) 128 (22): 3750.

https://doi.org/10.1182/blood.V128.22.3750.3750

Published: 2016

Journal Articles

Clinical Trial Results from the Subgroup of Lymphoma/CLL in a Phase 1 Study of ARQ 092, a Novel Pan AKT-Inhibitor

Wael Harb, Mansoor N. Saleh, MD, Kyriakos P Papadopoulos, MD, Feng Chai, MD, Maria Larmar, Giovanni Abbadessa, MD, Brian Schwartz, MD, Anthony Tolcher, MD

Blood (2015) 126 (23): 5116.

https://doi.org/10.1182/blood.V126.23.5116.5116

Published: 2015

Journal Articles

Update On The Safety and Efficacy Of EXTENDed Treatment With Eltrombopag (EPAG) In Adults With Chronic Immune Thrombocytopenia (ITP)

James B. Bussel, MD, Mansoor N. Saleh, MD, Raymond S.M. Wong, Paul Burgess, Kalpana Bakshi, BS, MS, Geoffrey W. Chan, MD, Christine K. Bailey, PhD

Blood (2013) 122 (21): 2315.

https://doi.org/10.1182/blood.V122.21.2315.2315

Published: 2013

Journal Articles

Comparison Of Two Dosing Schedules For Subcutaneous Injections Of Low-Dose Anti-CD20 Veltuzumab In Relapsed Immune Thrombocytopenia: Final Results Of a Phase I Study

Howard Liebman, MD, James B Bussel, MD, Mansoor N Saleh, MD, Heather Horne, William A Wegener, MD, PhD, David M Goldenberg, ScD, MD

Blood (2013) 122 (21): 1080.

https://doi.org/10.1182/blood.V122.21.1080.1080

Published: 2013

Journal Articles

Safety and efficacy of eltrombopag for treatment of chronic immune thrombocytopenia: results of the long-term, open-label EXTEND study

Mansoor N. Saleh, James B. Bussel, Gregory Cheng, Oliver Meyer, Christine K. Bailey, Michael Arning, Andres Brainsky

Blood (2013) 121 (3): 537–545.

https://doi.org/10.1182/blood-2012-04-425512

Published: 2013

Includes: Supplemental data

Journal Articles

Treatment Patterns Among Patients with Philadelphia Chromosome Positive Chronic Myeloid Leukemia (Ph+ CML) Treated with Imatinib in a Community Setting.

Kavita R Sail, MS, PhD, Lei Chen, MD, PhD, James Jackson, PharmD, MPH, Solveig G. Ericson, MD, PhD, Sally Haislip, RPh, Tamara Ibison, RN, James Gilmore, PharmD, Mansoor N Saleh, MD

Blood (2012) 120 (21): 3179.

https://doi.org/10.1182/blood.V120.21.3179.3179

Published: 2012

Journal Articles

Monitoring Patterns and Subsequent Outcomes Among Patients with Philadelphia Chromosome Positive Chronic Myeloid Leukemia (Ph+ CML) Treated with Imatinib in a Community Setting

James Jackson, PharmD, MPH, Lei Chen, MD, PhD, Kavita R Sail, MS, PhD, Solveig G. Ericson, MD, PhD, Sally Haislip, RPh, Joyce Sharpe, RN, James Gilmore, PharmD, Mansoor N Saleh, MD

Blood (2012) 120 (21): 2066.

https://doi.org/10.1182/blood.V120.21.2066.2066

Published: 2012

Journal Articles

Long-Term Safety and Efficacy of Eltrombopag in Adults with Chronic Immune Thrombocytopenia (ITP): Report of up to 5.5 Years of Treatment in EXTEND.

Mansoor N Saleh, MD, Gregory Cheng, James B Bussel, MD, Paul Burgess, Kalpana Bakshi, BS, MS, Andres Brainsky, MD, Christine K Bailey, PhD

Blood (2012) 120 (21): 2198.

https://doi.org/10.1182/blood.V120.21.2198.2198

Published: 2012

Journal Articles

Dynamics of Improvement in Health-Related Quality of Life (HRQoL) with Long-Term Eltrombopag Treatment in Adults with Chronic Immune Thrombocytopenia (ITP) in EXTEND.

Kelly M Grotzinger, James B Bussel, MD, Mansoor N Saleh, MD, Christine Bieri, MBA, Yuliya Orlova, Andres Brainsky, MD

Blood (2012) 120 (21): 2199.

https://doi.org/10.1182/blood.V120.21.2199.2199

Published: 2012

Journal Articles

Phase I/II Study of Monotherapy with Subcutaneous Injections of Low-Dose Anti-CD20 Veltuzumab in Relapsed Immune Thrombocytopenia

Howard A. Liebman, MA, MD, Mansoor N Saleh, MD, James B. Bussel, MD, O George Negrea, MD, Heather Horne, William Wegener, MD, PhD, David M Goldenberg, ScD, MD

Blood (2012) 120 (21): 622.

https://doi.org/10.1182/blood.V120.21.622.622

Published: 2012

Journal Articles

Safety and Efficacy of Extended Treatment with Eltrombopag in Adults with Chronic Immune Thrombocytopenia (ITP) From June 2006 to February 2011,

Mansoor N Saleh, MD, Gregory Cheng, MD, PhD, James B Bussel, MD, Paul Burgess, Lisa Marcello, BA, MS, Christine K Bailey, PhD, Andres Brainsky, MD

Blood (2011) 118 (21): 3296.

https://doi.org/10.1182/blood.V118.21.3296.3296

Published: 2011

Journal Articles

Phase I/II Study of Subcutaneous Injections of Low-Dose Anti-CD20 Veltuzumab in Relapsed Immune Thrombocytopenia,

Howard A Liebman, MD, Mansoor N Saleh, MD, James B Bussel, MD, Zale P Bernstein, MD, O George Negrea, MD, Anthony C Onyegbula, DO, Charles M Farber, MD, PhD, Heather Horne, William A Wegener, MD, PhD, David M Goldenberg, ScD, MD

Blood (2011) 118 (21): 3302.

https://doi.org/10.1182/blood.V118.21.3302.3302

Published: 2011

Journal Articles

Tositumomab and I 131 Tositumomab Achieves Complete Remissions Lasting > 10 Years In Patients with Chemotherapy-Refractory Low-Grade and Transformed B-Cell Lymphomas

Mark S. Kaminski, MD, Andrew D. Zelenetz, MD, Oliver W. Press, MD, PhD, Mansoor N. Saleh, MD, John P. Leonard, MD, Louis Fehrenbacher, MD, T. Andrew Lister, MD, Thierry J. Horner, PhD, Vanessa C. Williams, MS, Thomas S. Lin, MD, PhD, Christina Vleisides, DC, Susan J. Knox, MD, PhD, Richard L. Wahl, MD, Julie M. Vose

Blood (2010) 116 (21): 3960.

https://doi.org/10.1182/blood.V116.21.3960.3960

Published: 2010

Journal Articles

EXTEND Study Update: Safety and Efficacy of Eltrombopag In Adults with Chronic Immune Thrombocytopenia (ITP) From June 2006 to February 2010

Mansoor N. Saleh, MD, Gregory Cheng, MD, PhD, James B. Bussel, MD, Huiping Sun, Bhabita Mayer, MSc, Christine Bailey, PhD, Andres Brainsky, MD

Blood (2010) 116 (21): 67.

https://doi.org/10.1182/blood.V116.21.67.67

Published: 2010

NARROW

Treatment of Immune Thrombocytopenia (ITP) with Eltrombopag (EPAG) in Patients Who Did and Did Not Receive Prior Rituximab (Ritux): A Post-Hoc Analysis of the Extend Study

Safety and efficacy of long-term treatment of chronic/persistent ITP with eltrombopag: final results of the EXTEND study

Occurrence and Management of Cataracts in Adult Patients (pts) with Chronic Immune Thrombocytopenia (cITP) during Long-Term Treatment with Eltrombopag (EPAG): Results from the Extend Study

Hepatobiliary and Thromboembolic Events during Long-Term E.X.T.E.N.Ded Treatment with Eltrombopag in Adult Patients with Chronic Immune Thrombocytopenia (ITP)

Efficacy of Eltrombopag in Adult East Asian and Non-East Asian Patients with Chronic Immune Thrombocytopenia (cITP): Results from the Extend Study

Improvements in Patient Health-Related Quality of Life (HRQoL) with Clinical Efficacy in Patients Treated with Eltrombopag: Final Results from the Long-Term, Open-Label Extend Study

Patient-Reported Health-Related Quality of Life Improves over Time in Patients with Chronic Immune Thrombocytopenia Receiving Long-Term Treatment with Eltrombopag

Clinical Trial Results from the Subgroup of Lymphoma/CLL in a Phase 1 Study of ARQ 092, a Novel Pan AKT-Inhibitor

Update On The Safety and Efficacy Of EXTENDed Treatment With Eltrombopag (EPAG) In Adults With Chronic Immune Thrombocytopenia (ITP)

Comparison Of Two Dosing Schedules For Subcutaneous Injections Of Low-Dose Anti-CD20 Veltuzumab In Relapsed Immune Thrombocytopenia: Final Results Of a Phase I Study

Safety and efficacy of eltrombopag for treatment of chronic immune thrombocytopenia: results of the long-term, open-label EXTEND study

Treatment Patterns Among Patients with Philadelphia Chromosome Positive Chronic Myeloid Leukemia (Ph+ CML) Treated with Imatinib in a Community Setting.

Monitoring Patterns and Subsequent Outcomes Among Patients with Philadelphia Chromosome Positive Chronic Myeloid Leukemia (Ph+ CML) Treated with Imatinib in a Community Setting

Long-Term Safety and Efficacy of Eltrombopag in Adults with Chronic Immune Thrombocytopenia (ITP): Report of up to 5.5 Years of Treatment in EXTEND.

Dynamics of Improvement in Health-Related Quality of Life (HRQoL) with Long-Term Eltrombopag Treatment in Adults with Chronic Immune Thrombocytopenia (ITP) in EXTEND.

Phase I/II Study of Monotherapy with Subcutaneous Injections of Low-Dose Anti-CD20 Veltuzumab in Relapsed Immune Thrombocytopenia

Safety and Efficacy of Extended Treatment with Eltrombopag in Adults with Chronic Immune Thrombocytopenia (ITP) From June 2006 to February 2011,

Phase I/II Study of Subcutaneous Injections of Low-Dose Anti-CD20 Veltuzumab in Relapsed Immune Thrombocytopenia,

Tositumomab and I 131 Tositumomab Achieves Complete Remissions Lasting > 10 Years In Patients with Chemotherapy-Refractory Low-Grade and Transformed B-Cell Lymphomas

EXTEND Study Update: Safety and Efficacy of Eltrombopag In Adults with Chronic Immune Thrombocytopenia (ITP) From June 2006 to February 2010

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only